Communiqués Bristol-Myers Squibb Company Lima

Actions

BMY

US1101221083

Temps réel estimé Cboe BZX Autres places de cotation 20:05:57 27/06/2024			Varia. 5j.	Varia. 1 janv.
41,7 ^USD	+1,25 %		+0,64 %	-19,81 %

14:32	Purple Biotech déclare que les données intermédiaires de l'étude sur le cancer du pancréas sont prometteuses	MT
26/06	2seventy bio vend son programme sur l'hémophilie A et sa technologie d'édition de gènes à Novo Nordisk ; les actions montent après les heures de bureau	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab	24/06	AQ
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)	22/06	BU
European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab	21/06	BU
Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024	20/06	BU
Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors	18/06	BU
Bristol Myers Squibb Announces Dividend	18/06	BU
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors	13/06	BU
Bristol Myers Squibb Announces Opdivo Plus Yervoy Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma	05/06	AQ
Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial	04/06	BU
Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference	04/06	BU
Bristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting	03/06	BU
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer	03/06	BU
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer	01/06	BU
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma	30/05	BU
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma	29/05	BU
Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms	23/05	BU
Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting	23/05	BU
Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab	22/05	AQ
Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries	22/05	BU
Hawaii court orders drug companies to pay $916 million in Plavix blood thinner lawsuit	22/05	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

Christopher Boerner, PDG de Bristol-Myers : Un pipeline de 16 traitements, focus sur les neurosciences et l'oncologie

Le 09 janvier 2024 à 19:06